Yes, absolutely, the patents go hand-in-hand with the orphan drug designation. There will always be gaps and it is probably impossible to cover them all. Hopefully Race can cover enough that it is financially unprofitable for another company to attempt to work around everything they have in place. As you said, the arrangement with Prof Chen gives confidence in that regard.
Edit: replying to @johndprent, lost link.
General Comments / Chat, page-4120
-
- There are more pages in this discussion • 7,099 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.74 |
Change
0.010(0.58%) |
Mkt cap ! $295.5M |
Open | High | Low | Value | Volume |
$1.76 | $1.77 | $1.60 | $400.7K | 236.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 550 | $1.67 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.75 | 400 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 550 | 1.670 |
1 | 1000 | 1.660 |
1 | 8000 | 1.650 |
1 | 3000 | 1.640 |
1 | 2450 | 1.630 |
Price($) | Vol. | No. |
---|---|---|
1.750 | 400 | 1 |
1.755 | 990 | 1 |
1.770 | 3500 | 1 |
1.820 | 1030 | 2 |
1.835 | 12000 | 1 |
Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online